Canalblog
Editer l'article Suivre ce blog Administration + Créer mon blog
Publicité
Neuroptis Dry Eye Project with ML 7 (Myosin Light Chain Inhibitor)
1 décembre 2015

NEW PUBLICATIONS UPTO NOV. 27TH 2015

297_fig02

NEW PUBLICATIONS UPTO NOV. 27TH 2015

 

 

 



 

 

1. Curr Med Res Opin. 2015 Nov 27:1-26. [Epub ahead of print]
Kong X1Yan C1Ma W1Li Y1Xing B1Yang Y1Wang R1.

Author information: 

  • 1a Department of Neurosurgery , Peking Union Medical College Hospital, Chinese Academy of Medical Sciences . Beijing , China.

 

Abstract

Background and Aims Several studies in the past have attempted to demonstrate the efficacy of sodium hyaluronate in the treatment of xerophthalmia. However, results have been conflicting and a definite conclusion has not yet been reached. In order to provide integrated evidence for the effectiveness of sodium hyaluronate and to judge the methodological value of relevant randomized controlled trials (RCTs) in nearly thirty years, we conducted this meta-analysis. Methods A range of electronic databases were searched: MEDLINE, the Cochrane Library Database, EMBASE, CINAHL, Web of Science and the Chinese Biomedical Database (CBM) without language restrictions. Two independent reviewers assessed trials for eligibility and quality, and meta-analysis was performed using the STATA 12.0 software. Integrated odd ratio (OR) with its corresponding 95% confidence interval (95%CI) was calculated. Results Six RCTs were included with a total of 839 xerophthalmia patients. The meta-analysis results revealed that patients with xerophthalmia who received the intervention of sodium hyaluronate eye drops didn't have significantly higher remission rate of dry eye symptoms than those in controlled groups (OR = 1.811, 95% CI = 0.741∼4.429, p = 0.193). Sensitivity analysis suggested the statistical results were robust. No publication bias was detected in this meta-analysis (P>0.05). Conclusion Although sodium hyaluronate can be used to help relieve the symptoms of dry eyes, present evidences cannot show in unequivocal terms that patients with xerophthalmia can benefit more from the clinical application of sodium hyaluronate than other eye drops or therapies.

  PMID: 26613131 [PubMed - as supplied by publisher]
  Similar articles
  Icon for Taylor & Francis 

2. Ther Deliv. 2015 Oct;6(10):1211-9. doi: 10.4155/tde.15.55. Epub 2015 Oct 8.

Author information: 

  • 1Department of Pharmaceutical Technology, Institute of Pharmacy, Center for Molecular Biosciences Innsbruck, University of Innsbruck Innrain 80/82, 6020 Innsbruck, Austria.

 

Abstract
BACKGROUND: 

Dry eye - a disease affecting between 4 and 34% of the population worldwide. Stressful conditions to ocular surface, contact lenses as well as systemic disease cause dry eye. Novel synthesized hyaluronic acid derivate was evaluated in terms of its potential as mucoadhesive and lubricant. Results & methodology: Hyaluronic acid was chemically modified with cysteine ethyl ester (hyaluronic acid-cysteine ethyl ester). Mucoadhesion, disintegration and water uptake capacity, moreover, safety as the hen's egg test for mucous membrane compatibility were evaluated. According to the results, hyaluronic acid-cysteine ethyl ester achieved 3.81-fold increased swelling capacity, 30.5-fold more improvement mucoadhesive properties and 9.72-fold higher stability of hyaluronic acid, which was achieved due to the chemical modification.

SUMMARY: 

Thus, the promising results underpin further exploitation of this versatile polysaccharide for treating dry eye syndrome.

  PMID: 26606856 [PubMed - in process]
  Similar articles
  Icon for Atypon 

3. Ultrasound Med Biol. 2015 Oct 23. pii: S0301-5629(15)00534-7. doi: 10.1016/j.ultrasmedbio.2015.09.001. [Epub ahead of print]

Author information: 

  • 1Sunnybrook Research Institute, Toronto, Ontario, Canada; Department of Applied Mathematics, University of Waterloo, Waterloo, Ontario, Canada.
  • 2Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada.
  • 3Sunnybrook Research Institute, Toronto, Ontario, Canada.
  • 4Department of Anatomic Pathology, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
  • 5Sunnybrook Research Institute, Toronto, Ontario, Canada; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada. Electronic address: stuart@sri.utoronto.ca.

 

Abstract

Dry eye disease is a disorder of the ocular surface that causes pain and low vision in a significant portion of the adult population. A common cause is obstructive Meibomian gland dysfunction, whereby the Meibomian glands secrete abnormal meibum with a melting point elevated by 3°C-4°C; hence, hyperthermia is the typical treatment. A design is proposed for an ultrasound hyperthermia device made of a transducer contained inside a contact lens with an internal air gap. The transducer heats the posterior of the tarsus, and the air gap provides an air backing to the transducer, preventing direct heating of the cornea. A prototype device was built, and hyperthermia experiments were performed on a porcine subject in vivo. A therapeutic temperature rise of 5°C-7°C was achievable in 10-15 min. The temperature of the cornea did not rise more than 2°C during any of the experiments.

Crown Copyright © 2015. Published by Elsevier Inc. All rights reserved.

  PMID: 26603735 [PubMed - as supplied by publisher]
  Similar articles
  Icon for
Elsevier Science 

4. Ophthalmologe. 2015 Nov 24. [Epub ahead of print]
[Article in German]

Author information: 

  • 1Klinik für Augenheilkunde, Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353, Berlin, Deutschland. tina.dietrich-ntoukas@charite.de.
  • 2Kompetenzzentrum okuläre GvHD, Zentrum für Augenheilkunde, Universität zu Köln, Kerpenerstraße 62, 50937, Köln, Deutschland. philipp.steven@uk-koeln.de.
  • 33 Cellular Stress Responses in Aging-associated Diseases, CECAD, Universität zu Köln, Köln, Deutschland. philipp.steven@uk-koeln.de.

 

Abstract

Ocular graft-versus-host disease (GvHD) is predominantly an inflammatory ocular surface disorder after allogeneic hematopoietic stem cell transplantation (HSCT) with increasing incidence. It is not only associated with reduced quality of life because of dry eye syndromes but can also impair visual acuity and lead to blindness due to corneal complications. The GvHD is mostly associated with severe moisturizing disorder of the ocular surface, which is often resistant to therapy and accompanied by chronic inflammation. Corneal complications are an important problem in these patients. An individually adapted multimodal stage-related and interdisciplinary therapy in cooperation with hematologists and oncologists is therefore important for the treatment of patients with ocular GvHD.

  PMID: 26602095 [PubMed - as supplied by publisher]
  Similar articles
  Icon for Springer 

5. Trends Mol Med. 2015 Nov 17. pii: S1471-4914(15)00191-4. doi: 10.1016/j.molmed.2015.10.001. [Epub ahead of print]

Author information: 

  • 1Duke-NUS Graduate Medical School, Singapore.
  • 2Singapore Lipidomics Incubator, Life Sciences Institute, National University of Singapore, Singapore; Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Department of Biological Sciences, National University of Singapore, Singapore.
  • 3Duke-NUS Graduate Medical School, Singapore; Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Ocular Surface Research Group, Singapore Eye Research Institute, Singapore; Department of Cornea and External Eye Disease, Singapore National Eye Center, Singapore. Electronic address: Louis.tong.h.t@snec.com.sg.

 

Abstract

Ocular surface diseases such as dry eye, allergic keratoconjunctivitis, and infection are very prevalent conditions and involve ocular surface stress and inflammation. Recently, various lipid-based therapies have been advocated for the modulation of ocular surface inflammation. Here we review the latest developments and challenges of these strategies. These include administration of essential fatty acids, cyclooxygenase (COX) inhibitors and resolvin analogs. Lipids form part of the tear film and are crucial for tear film stability; loss of tear film stability can aggravate ocular surface inflammation. Strategies to replenish tear film lipids - namely, eyelid warming and eye drops containing natural or synthetic lipids - are evaluated. Recent advances in the use of lipids as ocular drug delivery vehicles, antioxidants, and diagnostic markers are discussed.

Copyright © 2015 Elsevier Ltd. All rights reserved.

  PMID: 26596867 [PubMed - as supplied by publisher]
  Similar articles
  Icon for Elsevier Science 

6. Clin Chest Med. 2015 Dec;36(4):669-83. doi: 10.1016/j.ccm.2015.08.009.

Author information: 

  • 1Vitreoretinal and Uveitis Service, Legacy Devers Eye Institute, 1040 Northwest 22nd Avenue Suite 168, Portland, OR 97210, USA. Electronic address: spasadhi@LHS.ORG.
  • 2Legacy Devers Eye Institute, 1040 Northwest 22nd Avenue Suite 168, Portland, OR 97210, USA.

 

Abstract

Sarcoidosis is one of the leading causes of inflammatory eye disease. Ocular sarcoidosis can involve any part of the eye and its adnexal tissues and may cause uveitis, episcleritis/scleritis, eyelid abnormalities, conjunctival granuloma, optic neuropathy, lacrimal gland enlargement, and orbital inflammation. Glaucoma and cataract can be complications from inflammation itself or adverse effects from therapy. Ophthalmic manifestations can be isolated or associated with other organ involvement. Patients with ocular sarcoidosis can present with a wide range of clinical presentations and severity. Multidisciplinary approaches are required to achieve the best treatment outcomes for both ocular and systemic manifestations. 

Copyright © 2015 Elsevier Inc. All rights reserved.

  PMID: 26593141 [PubMed - in process]
  Similar articles
Publicité
Publicité
Commentaires
Publicité
Neuroptis Dry Eye Project with ML 7 (Myosin Light Chain Inhibitor)
Newsletter
Visiteurs
Depuis la création 33 335
Publicité